All In Biotech

Drug Trial Radar · NCT05770609

A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Dose-finding Phase II Clinical Study to Evaluate the Efficacy and Safety of SPH3127 Tablets in the Treatment of Mild to Moderate Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Aug 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

53

Actual

Start

Jun 19, 2023

Primary completion

Sep 13, 2024

Study completion Sep 13, 2024

Sponsor

Sponsor type
Industry
First posted
Mar 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To preliminarily evaluate the clinical efficacy of the renin inhibitor SPH3127 Tablets in patients with mild to moderate ulcerative colitis with placebo as a control and determine the recommended dose.

Conditions

  • Mild to Moderate Ulcerative Colitis

Interventions

  • SPH3127 Tablets with Dose ADrug

    See Arm description

  • SPH3127 Tablets with Dose BDrug

    See Arm description

  • SPH3127 Tablets placeboDrug

    See Arm description

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Symptom remission rateTime frame: Week8
  2. Endoscopic remission rateTime frame: Week8

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chao-Yang Hospital,Capital Medical University

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • Chifeng Municipal Hospital

    Chifeng, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • Shanghai Jiaotong University School of Medicine, Renji Hospital

    Shanghai, China

  • Tianjin Medical University General Hospital;

    Tianjin, China

  • The First Affiliated Hospital,Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The Sixth Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Huizhou First Hospital

    Huizhou, Guangdong, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guanmgdong, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, He'nan, China

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The First Affiliated Hospital of Henan University

    Kaifeng, Henan, China

  • Union Hospital Tongji Medical College Huazhong Universitu of Science and Technology

    Wuhan, Hubei, China

  • Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • The First Hospital of Hunan University of Chinese Medicine

    Changsha, Hunan, China

  • The First Affiliated Hospital of University of South China

    Hengyang, Hunan, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • Shengjing Hospital affiliated to China Medical University

    Shenyang, Liaoning, China

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, China

  • Shandong Provincial Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, China

  • Xi'an Central Hospital

    Xi’an, Shanxi, China

  • Suining Central Hospital

    Suining, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.